





GC-MS Gas Chromatograph - Mass Spectrometer

Analysis of Potential Genotoxic Impurities in Active Pharmaceutical Ingredients (5) - Analysis of Alkyl Halides -

Alkyl halides are used as an alkylating agent for raw ingredients in the synthesis of pharmaceuticals or are generated as a byproduct of drug synthesis. They have been identified as potential carcinogens or genotoxins. This Application Data Sheet shows an example of analyzing 18 alkyl halides using headspace-GC-MS.

Experimental

Standard mixtures were prepared by diluting 18 types of alkyl halides in methanol to 0.2, 2, 10, 20, and 100 μ g/mL concentrations. An internal standard solution was prepared by diluting fluorobenzene in methanol to a 20 μ g/mL concentration. Test samples were prepared by placing 20 mg of the pharmaceutical ingredients in a 20 mL screw-cap vial (La-Pha-Pack P/N: 18 09 1307), diluting it with 10 mL of Milli-Q water, adding 10 μ L of the internal standard solution, and then quickly sealing the vial by screwing on the magnetic screw-cap (La-Pha-Pack P/N: 18 09 1309). Standard aqueous samples were prepared by adding 10 μ L of each standard alkali halide mixture and 10 μ L of the internal standard solution to 10 mL Milli-Q water. The concentrations of the prepared standard aqueous samples were 0.2, 2, 10, 20, and 100 ng/mL (equivalent to 0.1, 1, 5, 10, and 50 ng/mg concentrations in the active pharmaceutical ingredients), respectively.

Analytical Conditions

FASST (Fast Automated Scan/SIM Type), which is capable of simultaneous Scan and SIM measurements, was used as the measurement mode. The analysis conditions are shown in Table 1.

Table 1: Analytical Conditions

GC-MS :GCMS-QP2 Autosampler :AOC-5000 F Column :Rtx-1 (60 m		2010 Ultra Plus (HS) m length, 0.25	mm I.D., df=1.0 µm)			
Glass Insert	:Deactivate	d Split insert wi	th wool (PN: 225-20803-07	1)		
[AOC-5000 Plus (HS)] Incubation Temp. :80 °C Incubation Time :30 min Syringe Temp. :100 °C Agitator Speed :250 rpm Fill Speed :500 μL/s Pull Up Delay :500 mse		; m ./sec isec	[GC] Injection Temp. Column Oven Temp. Injection Mode Carrier Gas Flow Control Mode Split Ratio	:230 °C :40 °C (2 min) → (20 ° :Split :Helium :Linear velocity (25.5 ci :10	n) → (20 °C/min) → 250 °C (4 min) ity (25.5 cm/sec)	
Inject to Injection Spee Pre Inject Dela Flush Time GC Run Time Injection Volur	:GC Inj d :500 μL y :500 m :5 min :25 min ne :1 mL	1 ./sec sec	[MS] Interface Temp. Ion source Temp. Tuning Mode Measurement mode Scan Mass Range Scan Event Time Scan Speed SIM Event Time	:230 °C :230 °C :High sensitivity :FASST (simultaneous : <i>m</i> /z 30 - 270 :0.05 sec :10,000 <i>u</i> /sec :0.3 sec	Scan/SIM measur	ements)
Chloromethane Vinyl chloropropa Iodomethane 1-Chloropropa <i>trans</i> -1,2-Dichl 2-Bromopropa <i>cis</i> -Dichloroeth 2-Chloroacrylo 1-Chloro-2-me	ne ne oroethylene ne ylene nitrile thylpropene	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1-Bromopro 2-lodoprop Fluorobenz 1-Bromo-2- 1-lodoprop <i>trans</i> -1,2-D <i>cis</i> -1,2-Dibu <i>trans</i> -3-Bro <i>cis</i> -3-Brom	opane ane rene -methylpropene ane ibromoethylene romoethylene mo-2-methylacrylonitrile o-2-methylacrylonitrile	43, 122 43, 170 96, 70 55, 134 43, 170 186, 105 186, 105 66, 145 66, 145	

LAAN-J-MS-E046

Results

The total ion current chromatogram for the 100 ng/mL concentration standard aqueous solution (equivalent to 50 ng/mg concentration* in the active pharmaceutical ingredients) is shown in Fig. 3. The SIM chromatograms for six typical components in the 0.2 ng/mL concentration standard aqueous solution (equivalent to 0.1 ng/mg concentration* in the pharmaceutical) are shown in Fig. 4.



* 1,2-Dibromoethylene and 3-Bromo-2-methylacrylonitrile concentrations include both cis and trans forms.

Fig. 3: Total Ion Current Chromatogram





For Research Use Only. Not for use in diagnostic procedures.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice

Shimadzu Corporation www.shimadzu.com/an/